Company profile
ARVINAS, INC.
NASDAQ:ARVNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BAVDEGALUTAMIDE | phase1_2 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04072952 | phase1_2 | completed | 2019-09-22 | 2024-09-13 | Arvinas Estrogen Receptor, Inc. | A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer |
| NCT06393738 | phase1 | recruiting | 2024-09-05 | 2028-03-01 | Arvinas Inc. | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. |
| NCT07749586 | phase1_2 | recruiting | 2026-07-29 | 2031-03-31 | Arvinas Inc. | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors |
| NCT07023731 | phase1_2 | active_not_recruiting | 2025-05-29 | 2026-11-30 | Arvinas Inc. | A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation |
| NCT05549505 | phase2 | completed | 2023-02-15 | 2024-07-13 | Arvinas Inc. | A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery |
FDA applications (0)
No records yet.